Drug Approval | January 20, 2022
Australia grants provisional registration for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
This is the company’s first partnership arrangement in China
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Subscribe To Our Newsletter & Stay Updated
